摘要
目的观察参麦注射液联合环磷腺苷葡胺注射液治疗冠心病心力衰竭的效果。方法按照入院顺序抽取我院自2015年1月至2017年1月收治的冠心病心力衰竭患者90例,分为联合组(n=45)和常规组(n=45)。常规组进行常规治疗,联合组在常规组的基础上进行参麦注射液联合环磷腺苷葡胺注射液治疗。对比两组的治疗效果以及心功能(LVEF、LVEDD、LVESD)。结果与常规组的治疗效果比较,联合组的较高;与常规组的心功能比较,联合组的较优,差异有统计学意义(P<0.05)。结论参麦注射液联合环磷腺苷葡胺注射液治疗冠心病心力衰竭,患者的临床症状以及心功能得到了显著的改善,值得借鉴和推广。
Objective To observe the effect of Shenmai injection combined with Meglumine Adenosine Cyclophosphate Injection in the treatment of coronary heart disease and heart failure. Methods From January 2015 to January 2017,90 patients with coronary heart disease and heart failure were selected in our hospital. They were divided into combined group（ n = 45） and routine group（ n = 45）. The routine group received routine treatment,and the combination group was treated with Shenmai injection combined with Meglumine Adenosine Cyclophosphate Injection on the basis of routine group. The therapeutic effect and cardiac function（ LVEF,LVEDD,LVESD） were compared between the two groups. Results Compared with the conventional group,the combination group was higher,the heart function of the routine group was better than that of the conventional group,and the difference was significant（ P 0. 05）. Conclusion Shenmai injection combined with Meglumine Adenosine Cyclophosphate Injection in the treatment of coronary heart disease,heart failure patients with clinical symptoms and cardiac function has been significantly improved,it is worthy of reference and promotion.
出处
《辽宁医学杂志》
2017年第4期10-11,共2页
Medical Journal of Liaoning
关键词
参麦注射液
环磷腺苷葡胺
冠心病
心力衰竭
Shenmai injection
Meglumine adenosine monophosphate
Coronary heart disease
Heart failure
